• There is still a need for novel therapeutic approaches for hemophilia A patients with inhibitors.
Summary. Background: Today, the most serious complication for patients with hemophilia A undergoing factor VIII (FVIII) replacement therapy is the development of neutralizing antibodies (inhibitors). Although inhibitors can be eradicated by application of high doses of FVIII, the immune tolerance induction therapy fails in up to 30% of patients. Hence, there is still an urgent need for novel therapeutic approaches for patients with persisting inhibitors. Objectives: In the present study, the potential use of immunotoxins containing exotoxin A (ETA) from Pseudomonas aeruginosa for selective elimination of FVIII-specific B cells was explored. Methods: The immunodominant C2 domain of human FVIII was used as a targeting moiety instead of the full-length FVIII protein and the resulting human C2 domain-ETA fusion protein (hC2-ETA) was produced in Escherichia coli. Results: Binding studies with monoclonal C2 domain-specific antibodies confirmed the conformational integrity of the C2 domain in hC2-ETA. The functionality of hC2-ETA was tested ex vivo by incubation of splenocytes from inhibitor-positive FVIII knockout mice with hC2-ETA and controls. FVIII-specific memory B cells from splenocytes were differentiated by FVIII stimulation in antibody-secreting cells (ASC) and detected by an enzyme-linked immunospot assay. Although the controls showed no effect, incubation of splenocytes with hC2-ETA reduced the number of C2-specific ASC in a dose-dependent fashion, indicating specific and efficient elimination of C2-specific memory B cells. Conclusions: Overall, the results of the study support the fact that
Introduction
Hemophilia A is a congenital bleeding disorder caused by mutations in the factor VIII (FVIII) gene. Deficiency or defect of the FVIII protein in patients with hemophilia A leads to a severely impaired blood coagulation. Although treatment of patients with therapeutic FVIII restores hemostasis, up to 30% of patients develop neutralizing antibodies (inhibitors) against FVIII [1] [2] [3] . Patients with inhibitors can be treated with high doses of FVIII and immune tolerance is induced in around 70% of patients [4] . Patients with persisting inhibitors suffer from recurrent bleeding episodes and are affected by increased morbidity and mortality. Treatment of these patients is based on bypassing agents such as activated prothrombin complex concentrates or recombinant activated factor VII, which are expensive and have reduced efficacy compared with FVIII replacement therapy [5] . Novel treatment options including a bispecific antibody engaging factors IX(a) and X are emerging [6, 7] . Nevertheless, there is still a great need for novel approaches to induce tolerance and/or to treat patients with inhibitors. When the immune response to FVIII is established, memory B cells are crucial for maintaining and recalling the antigen-specific antibody responses. As the monoclonal antibody rituximab depletes CD20-positive memory B cells it has also been used for the eradication of inhibitors in patients with congenital and acquired hemophilia A [8, 9] . However, the unspecific depletion of the entire Bcell population is unfavorable because of the following immunodeficiency and adverse events described [10] . Therefore, specific targeting of the B-cell receptor (BCR) of FVIII-specific memory B cells presents a promising approach to minimize side-effects [11] . FVIII knockout (FVIII (À/À) ) mice have been used to characterize the immune response to FVIII as these mice develop high inhibitor titers upon FVIII injection [12, 13] . The antigenspecific approach for the selective elimination of FVIIIspecific B cells by a FVIII-toxin conjugate was first presented as a conference abstract [14] . The application of the FVIII-toxin conjugate in inhibitor-positive FVIII (À/À) mice resulted in long-term eradication of FVIII inhibitors. In addition, the application of the FVIII-toxin conjugate prevented de novo inhibitor formation in naive FVIII (À/À) mice when mice were subsequently immunized with FVIII. Despite these promising results, the use of FVIII for cell targeting of immunotoxins might be limited by its high molecular weight of approximately 250 kDa and its nonspecific binding, which could also lead to toxic effects on healthy tissue. Therefore, we explored the potential use of alternative immunotoxins in the current study.
It is known that the inhibitory immune response is primarily directed against the A2 and the C2 domain of FVIII [15] [16] [17] [18] [19] [20] [21] . Hence, the application of a single A2 and/ or C2-domain immunotoxin might allow targeting of a relevant number of FVIII-specific memory B cells [22] . For proof of concept studies, we developed a fusion protein consisting of the C2 domain of human FVIII (hC2) and a truncated version of Pseudomonas exotoxin A (ETA). ETA lacks the natural cell-binding domain, which is replaced by hC2 for targeted binding of the BCR on hC2-specific B cells. Antigen binding of the BCR causes receptor-mediated endocytosis followed by proteolytic cleavage and finally cytosolic release of the catalytic moiety of ETA [23, 24] . In the cytosol of the target cell ETA unfolds its cytotoxic activity through ADP-ribosylation of elongation factor 2, leading to inhibition of protein synthesis and subsequent apoptosis of the target cell [25, 26] . It has already been shown that the fusion of antigens to ETA is a promising approach for the specific depletion of B cells [24, 27] .
Here, we report on the development of a potent novel immunotoxin hC2-ETA for the selective elimination of hC2-specific B cells. We successfully produced hC2-ETA as a functional fusion protein with accurate folding properties. Moreover, hC2-ETA was able to selectively eliminate murine hC2-specific B cells in an efficient manner.
Materials and methods

Cloning and production of proteins
Human FVIII domain A2, C1 and C2 human serum albumin (HSA) fusion proteins were expressed and purified as previously described [28] [29] [30] .
The DNA sequence of the C2 domain of human FVIII [1] was cloned into the vector pSW220 [31, 32] (Fig. 1) .
One adenine was deleted from the vector pSW220 with the primers GAGCACCATCATCACCATC/AGTGT-GATGGTGATGATG using a Q5 Ò Site-Directed Muta- 30-fold in this medium and grown until reaching an OD 600 of 0.6. For the expression of recombinant proteins, IPTG was added to a final concentration of 0.25 mM for 3 h at 30°C and 180 rpm. Cells were harvested by centrifugation at 10 000 9 g for 10 min at 4°C and resuspended in ice-cold lysis buffer (50 mM Na 2 HPO 4 / NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole and 1 mM PMSF, pH 7). EDTA-free protease inhibitor cocktail tablets (Roche, Basel, Switzerland) were added to the extraction solutions according to the manufacturer's instructions. Bacterial cells were lysed via sonication on ice, and the lysate was cleared by centrifugation at 10 000 9 g at 4°C for 30 min and filtered through a 0.2-lm filter (Sarstedt, N€ umbrecht, Germany).
Purification of hC2-ETA and ETA
Lysates were loaded onto a prepacked HisTrap high performance column (GE Healthcare, Munich Germany) according to the manufacturer's instructions. Purification was performed on an € AKTAprime system (GE Healthcare, Little Chalfont, UK) with washing buffer containing 50 mM Na 2 HPO 4 /NaH 2 PO 4 , 300 mM NaCl and 10 mM imidazole (pH 7), and the proteins were eluted with a linear 10-250 mM imidazole gradient in the same buffer. Purified protein was dialyzed against lipolysaccharide (LPS) removal buffer (25 mM Na 2 HPO 4 /NaH 2 PO 4 , 400 mM NaCl, pH 6.0) using a 10 kDa molecular weight cut-off (MWCO) dialysis membrane, and a protein solution containing 2 mg protein was added to prepared Pierce TM High Capacity Endotoxin Removal Spin Columns (Thermo Fisher Scientific, Dreieich, Germany) for 2 h at room temperature. The purified protein was eluted through centrifugation and added to a Vivaspin concentrator with 30 kDa MWCO (GE Healthcare). The buffer was exchanged for LPS-free Dulbecco's phosphate-buffered saline (DPBS) (Thermo Fisher Scientific). The purity of the proteins was determined by SDS-PAGE and a Pierce antibody was used as a positive control. Bound murine or human antibodies were detected with horseradish peroxidase (HRP)-conjugated rat anti-mouse (Dianova, Hamburg, Germany) and with HRP-conjugated goat anti-human IgG (Caltag, Buckingham, UK), respectively. Antibody binding was visualized by addition of o-phenylenediamine (OPD, Sigma Aldrich) and absorbance measurements at 492 nm and 620 nm (reference).
FVIII knockout mice
Breeding pairs of B6;129S4-F8<tm1Kaz>/J (FVIII À/À ) mice with a targeted deletion in exon 16 of FVIII were purchased from Charles River Laboratories (Sulzfeld, Germany). Mice were bred under specific pathogen-free conditions. All studies were approved by the local authority for animal welfare (Regierungspr€ asidium Darmstadt, Gen.Nr. F 21/05).
In vitro stability of hC2-ETA Blood from naive FVIII (À/À) mice was obtained by cardiac puncture, and nine parts blood were mixed with one part sodium citrate (0.11 mol L À1 ) and centrifuged at 1500 9 g for 15 min to obtain plasma. The in vitro stability of hC2-ETA and recombinant FVIII (Kogenate Ò Bayer, Berlin, Germany) was evaluated by incubation of 164 pmol mL À1 in plasma or PBS for 0, 24 and 48 h at 37°C. Residual protein was determined by binding to a C2 domain-specific antibody (BO2C11) by ELISA. For this, 0.1 lg human mAb BO2C11 was coated overnight on microtiter plates at 4°C [33] , and 5% MPBST or 2% bovine serum albumin (BSA) served as blocking and dilution buffer for hC2-ETA and FVIII, respectively. Wells were blocked for 2 h at room temperature. Plasma samples and controls were serially diluted and added to the wells for 2 h at room temperature. Bound hC2-ETA was detected with HRP-conjugated ANTI-FLAG Ò M2 (Sigma Aldrich) antibody. Bound FVIII was detected with GMA 8006, which did not interfere with BO2C11 binding. Bound GMA 8006 was detected with an HRP-conjugated goat anti-mouse (Dianova) antibody. Antibody binding was visualized as described above.
Purification of FVIII heavy and light chains
The FVIII heavy chain (HC, A1-A2-B) and light chain (LC, A3-C1-C2) were purified by the dissociation of recombinant human FVIII (Kogenate Ò Bayer) as already described by Healey et al. [34] .
Immunization of FVIII knockout mice and detection of anti-FVIII antibodies
Eight-to 12-week-old mice were immunized intravenously with 2 IU FVIII (Kogenate Ò Bayer) weekly for 4 weeks.
One week after the last injection (day 27), blood was drawn from the tail vein. Plasma was obtained as described above. The presence of anti-FVIII antibodies was tested by ELISA as previously described [29] .
Blood sampling and spleen cell preparation
Mice with anti-FVIII antibodies present were intraperitoneally anesthetized with 100 mg kg À1 bodyweight ketamine and 10 mg kg À1 bodyweight xylazine [35] .
Blood was collected by cardiac puncture as described above. FVIII domain mapping of antibodies in the plasma was carried out as described previously [29] . Spleens were collected in RPMI 1640 culture medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS), 2% L-glutamine, 1% penicillin/ streptomycin and 50 lM b-mercaptoethanol, and chopped through a 70-lm nylon cell strainer (VWR International GmbH, Darmstadt, Germany). The cells were harvested by centrifugation for 6 min at 400 9 g and resuspended in DPBS (Thermo Fisher Scientific) containing 2% FBS. Red blood cells were lysed by adding BD Pharm Lyse TM Buffer (Becton Dickinson Biosciences, Heidelberg, Germany) for 10 min at 4°C according to the manufacturer's instructions. Afterwards, the cells were harvested by centrifugation and washed twice with DPBS containing 2% FBS. The cells were finally resuspended in supplemented culture medium as described above.
Ex vivo cytotoxicity assay
Prepared splenocytes were cultured at a concentration of 1.5 9 10 6 cells per mL in supplemented culture medium for 6 days. From day 0, cells were incubated in the presence of 0.04 nM FVIII for re-stimulation of memory B cells (Fig. 3A) . In addition, different concentrations of hC2-ETA, ETA or HSA-hC2 (final concentrations: 0.004 nM to 4 nM as indicated) were added to the cells. Antibody-secreting cells were visualized on day 6 by ELISPOT assay. For this, 2 pmol rFVIII (Kogenate Ò Bayer) or hC2-ETA was immobilized on polyvinylidene difluoride (PVDF)-bottomed 96-well Multiscreen-IP Filtration Plates (Millipore Corporation, San Francisco, CA, USA). After blocking the wells with 5% FBS in RPMI medium for 2 h at room temperature, the cells were incubated on the membrane for 5 h at 37°C and 5% CO 2 . The wells were washed four times each with PBS and PBST (PBS with 0.1% Tween 20). Antibodies were visualized using HRP-conjugated goat anti-mouse IgG (Dianova) in DPBS containing 2% BSA, and spots were developed using 3-amino-9-ethylcarbazole (Becton Dickinson Biosciences) as the substrate. Spots were counted and evaluated using the computer-based scanning system ELIScan and EliAnalyse (AELVIS, Hannover, Germany). All plates analyzed for this study were read at one time using the same settings.
Statistical analysis
Data evaluation and statistical analysis were accomplished using GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA). Data are presented as the means of duplicates AE standard deviation (SD). One-way ANOVA test and Tukey's multiple comparisons test were used to analyze the spot count, as a normal distribution was assumed.
Results
Characterization of hC2-ETA
For the construction of the immunotoxin, a truncated version of Pseudomonas exotoxin A (ETA) lacking the natural N-terminal cell-binding domain, which was replaced by the C2 domain of human FVIII (hC2), was used. Both hC2-ETA and the control toxin ETA without any cell-binding domain were bacterially produced.
Another control protein, HSA-hC2, was produced in HEK293T cells to investigate the impact of the hC2 domain (Fig. 1 ). All proteins were purified as described in the Materials and Methods. To test for correct folding of expressed proteins, binding of hC2-ETA to a panel of monoclonal anti-hC2 antibodies was analyzed by ELISA ( Fig. 2A) . These monoclonal antibodies (mAbs) are well characterized and known to recognize distinct conformational epitopes on the hC2 domain; therefore, they are an appropriate control for correct folding [33, [36] [37] [38] . Indeed, hC2-ETA was recognized by all anti-hC2 mAbs tested. This result suggests proper folding of the hC2 domain, despite being produced in a prokaryotic organism. HSAhC2 was also recognized by the same panel of anti-hC2 mAbs as previously described [29] . Next, the in vitro stability of hC2-ETA was examined in plasma from naive FVIII (À/À) mice and PBS. The level of intact hC2-ETA was measured by ELISA using human anti-hC2 mAb BO2C11 (Fig. 2B,C) . A decrease in the binding signal was interpreted as a loss of conformational integrity because of the denaturation of hC2-ETA.
Incubation of hC2-ETA at 37°C had an effect on the conformational integrity of the immunotoxin. After 24 h of incubation in plasma, 78% of the initial binding signal remained, and after 48 h, the binding signal dropped to 53% (Fig. 2B) . After incubation of hC2-ETA in PBS, the decrease in conformational integrity was similar, with 65% residual binding after 24 h of incubation and 50% residual binding after 48 h of incubation (Fig. 2C) . We also analyzed the in vitro stability of plasma-incubated FVIII (Fig. S1) . The binding signal of FVIII after 24 h of incubation in naive FVIII (À/À) plasma decreased by approximately 20% without any further decay after 48 h, suggesting the preservation of the conformational integrity of the hC2 domain. This result reveals that the hC2 domain within hC2-ETA is more vulnerable to degradation than the hC2 domain within FVIII. Nevertheless, stability was confirmed, and freshly prepared hC2-ETA was used for the experiments.
Elimination of hC2-specific B cells ex vivo
It has already been shown that FVIII-specific memory B cells can be restimulated into antibody-secreting cells (ASCs) ex vivo [39, 40] . We used this system to test the capacity of hC2-ETA to eliminate FVIII-specific memory B cells. Splenocytes from immunized FVIII (À/À) mice were restimulated with 0.04 nM FVIII ex vivo in the presence and absence of different concentrations of hC2-ETA, HSA-hC2 or ETA (Fig. 3A) . HSA-hC2 and ETA served as controls to evaluate the specific effects of the immunotoxin [40] . The differentiation of FVIII-specific memory B cells to FVIII-and hC2-specific ASCs was analyzed by ELISPOT assay (Fig. 3B-E) [39] . The incubation of splenocytes with FVIII and increasing amounts of hC2-ETA showed a concentration-dependent decrease in hC2-specific spots, suggesting the elimination of hC2-specific memory B cells (Fig. 3B,D) . Thus the addition of equimolar amounts of hC2-ETA (0.04 nM) compared with FVIII showed a significant reduction in hC2-specific spots (Fig. 3B) . Furthermore, the addition of a 100-fold excess (0.4 nM) of hC2-ETA compared with FVIII showed almost complete elimination of hC2-specific B cells concomitant with almost no hC2-specific spots on the ELISPOT membrane. Hausl et al. previously described that FVIII concentrations higher than 4 nM prevented the re-stimulation of FVIII-specific B cells into ASCs [40] . To exclude an effect due to the sole presence of the hC2 domain as such, HSA-hC2 was added as a control. The addition of HSA-hC2 at only the highest concentration (4 nM) led to a decrease in hC2-specific spots. ETA alone did not have any effect on spot counts at any concentration up to 4 nM tested (Fig. 3B,D) .
The effect of hC2-ETA on FVIII-specific B cells was only marginal (Fig. 3C,E) . Obviously, the effect is dependent on the amount of hC2-specific B cells in the FVIIIspecific repertoire, as the immune response to FVIII is polyclonal. We therefore analyzed the immune response of the immunized FVIII (À/À) mice by ELISA and revealed that the antibody response was, as expected, also directed against other FVIII domains in addition to the hC2 domain (Fig. S2) . Further results showed a more distinct decrease in FVIII-specific B cells in mice with a more pronounced hC2-specific antibody response (data not shown). Nevertheless, a slight reduction in FVIII-specific spots can be observed following the addition of 0.04 nM and higher concentrations of hC2-ETA. Similar to the results obtained with FVIII, the addition of 4 nM HSAhC2 also revealed a marginal decrease in FVIII-specific spots (Fig. 3C,E) [40] . In accordance with the analysis of hC2-specific B cells, the addition of ETA alone had no effect on FVIII-specific B cells (Fig. 3C,E) .
Discussion
The eradication of FVIII inhibitors in hemophilia A patients is still a major concern. Thus, novel strategies, such as the selective elimination of FVIII-specific B cells, are urgently needed for affected patients. In earlier studies, we specifically targeted FVIII inhibitor-producing cells with anti-idiotypic antibodies, which had been successfully isolated from phage-displayed antibody libraries [41] . Unfortunately, these anti-idiotypes failed to crossreact with inhibitors from murine or human plasma samples.
As the immune response is primarily directed against the A2 and C2 domain of FVIII, we explored the potential use of alternative immunotoxins in the current study. We successfully developed an immunotoxin consisting of One week after the last injection, spleens were obtained. Prepared splenocytes were re-stimulated into ASCs 6 days ex vivo in the presence of 0.04 nM FVIII. For the determination of cytotoxic activity, increasing amounts of hC2-ETA, ETA or HSA-hC2 were added at day 28 (day 0 of ex vivo incubation). (B-E) Elimination of hC2-specific B cells ex vivo. Splenocytes from immunized FVIII (À/À) mice were incubated for 6 days in the absence (À) or presence of 0.04 nM FVIII for the re-stimulation of FVIII-specific memory B cells into ASCs. At day 0 of ex vivo incubation, hC2-ETA, HSA-hC2 or ETA was added in increasing concentrations ranging from 0 to 4 nM to test the cytotoxic activity of the proteins. Newly formed anti-hC2 (B, D) and anti-FVIII ASCs (C, E) were detected by ELISPOT as described in the Materials and Methods. Experiments were performed twice with similar results. Spleens from four mice were pooled for preparation of splenocytes. Error bars represent the standard deviation (SD) of the mean of duplicates. P-values are indicated. ETA, exotoxin A; ASC, antibody-secreting cells. **P < 0.01; ***P < 0.001. the hC2 domain and a truncated version of Pseudomonas exotoxin A (ETA) to allow specific targeting of hC2-specific B cells in an ex vivo mouse model. The potential therapeutic relevance of A2 and C2 domains has already been suggested by data showing that B-cell presentation of A2 and C2 domains on an Ig backbone specifically prevented or decreased existing antibodies in FVIIIimmunized FVIII (À/À) (hemophilia A) mice [42] . We demonstrate the production of the correctly folded immunotoxin hC2-ETA in bacteria. The stability of hC2-ETA in the plasma of FVIII (À/À) mice was confirmed for the C2. As the activation of the toxin moiety depends on structural changes including reduction of disulfide bonds, conformational integrity of the ETA moiety was not further analyzed in this study [43] , but was demonstrated before [25, 44] . In particular, this result is of importance for in vivo application of hC2-ETA because the stability of the therapeutic protein is crucial for in vivo efficacy. In this study, hC2-ETA was able to specifically eliminate hC2-specific B cells in an ex vivo mouse model. By incubating splenocytes from immunized FVIII (À/À) -knockout mice with FVIII, FVIII-specific memory B cells differentiated to ASCs. Commonly, splenocyte pools used for restimulation studies are depleted of CD138 + plasma cells prior to incubation, resulting in a splenocyte pool excluding antibody-secreting cells [40, 45] . However, we used whole splenocytes that were not depleted of CD138 + plasma cells to more likely represent the situation in patients with existing inhibitors. In these experiments, all CD138 + plasma cells died after 6 days in culture, as no spots had been detected on the ELISPOT membrane when cells were incubated in the absence of FVIII.
Our results show that hC2-ETA eliminated hC2-specific B cells in a concentration-dependent manner. The addition of equimolar amounts of FVIII and hC2-ETA led to a significant reduction in hC2-specific spots, concurrently revealing high specificity. Moreover, by adding a 100-fold excess of hC2-ETA over FVIII, all hC2-specific memory B cells could be eliminated. High doses of FVIII have been previously shown to reduce the number of ASCs in a similar approach [22, 40] . To confirm toxin-dependent killing, HSA-hC2 was added as a control. The results revealed that 4 nM HSA-hC2 was necessary for a significant reduction in hC2-specific spots. In contrast, effects of the specific protein-toxin construct were seen at concentrations as low as 0.04 nM. In addition, ETA alone had no effect on the cells because of the lack of the targeting moiety. This result demonstrated that the elimination of hC2-specific B cells is dependent on the binding and internalization of hC2-ETA as well as the subsequent toxin-induced apoptosis of the target cell. As expected, the effect of hC2-ETA on the overall FVIII-specific spots was limited because of the diverse immune response in immunized mice. The apparently obvious alternative approach of using FVIII-toxin constructs has several disadvantages: the use of FVIII as the targeting moiety in a toxin can result in undesirable side-effects because of non-specific or specific binding; further the C2 domain interacts with endothelial cells and is involved in the immunogenic uptake of FVIII in dendritic cells [46, 47] . However, we could not detect any significant cytotoxic effects of hC2-ETA on human umbilical vein endothelial cells (Fig. S3) . In addition, hC2-ETA did not induce apoptosis when incubated with immature human monocyte-derived dendritic cells (Fig. S4) .
It is known that C2 and A2 domains significantly but not exclusively contribute to the FVIII-specific immune response also in mice [48] . Indeed, all other domains (C1, A1 and A3) can also contribute to the anti-FVIII repertoire, as shown in this study and in previously published work [13, 20, 29, 37, 49] (Fig. S2) . Therefore, this approach may be extended to further domains of FVIII for potential clinical application. We proved the feasibility of the use of FVIII domain immunotoxins for the selective elimination of FVIII-specific B cells. To reduce non-specific toxic effects, FVIII domain immunotoxins might be administered individually depending on the domain specificities of the patient's FVIII-specific immune response. Domain specificity could be determined by homolog scanning mutagenesis or other methods as recently described [29] .
Despite the promising results in the ex vivo mouse model, the immunogenicity and dose-limiting cytotoxicity of the toxin moiety (ETA) is a major concern with regard to in vivo application of FVIII domain ETA. We have also seen this when injecting hC2-ETA in FVIII-immunized FVIII (À/À) mice. This resulted in a complete elimination of hC2-specific B cells in three out of six mice and in a reduction in the others (data not shown). Dose-limiting toxicity of the toxins prevented further experiments to increase efficacy. Alternatively, extending the treatment phase most likely results in the development of neutralizing antibodies against ETA [32] . ETA-based recombinant immunotoxins have already been used in clinical applications, and therefore data concerning efficacy and sideeffects such as immunogenicity or ligand-independent dose-limiting toxicity are available [50] . Several approaches have been made regarding the reduction of immunogenicity by PEGylation, modification of B or T-cell epitopes or deletion of parts of the toxin moiety [51] . Unfortunately, most of these modifications also affect the cytotoxicity. The application of small cytotoxic chemical compounds or other apoptosis-inducing moieties could be a possible way to circumvent the problem of the immunogenicity of protein-based toxins. For cancer treatment, similar antibody-drug conjugates are used in preclinical and clinical applications with promising results [52, 53] . To specifically eliminate FVIII-specific B cells, the respective FVIII domains could be chemically coupled to a small cytotoxic moiety. This moiety should be able to exert its cytotoxic activity throughout the cell cycle because of the potential long lifespan of memory B cells [54, 55] . Because of in vitro coupling of the payload to the targeting moiety, all FVIII domains could therefore be produced in a mammalian cell line. This approach could also be beneficial for larger FVIII domains because protein size for recombinant expression in bacteria is limited. Furthermore, the production of FVIII domains in a mammalian cell line is more adequate than the production of these domains in a prokaryotic organism because of glycosylation patterns and further post-translational modifications.
In conclusion, we have developed hC2-ETA for use as a highly specific immunotoxin. hC2-ETA is capable of selectively and efficiently eliminating hC2-specific B cells. The application of FVIII domains as targeting agents for FVIII-specific B cells is a potential new strategy for their selective elimination and therefore might allow an individualized immune therapeutic approach for patients with hemophilia A and persisting inhibitors. 
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Supporting Information
Additional Supporting Information may be found in the online version of this article: Fig. S1 . Conformational integrity of FVIII after incubation at 37°C. In total, 16 pmol mL À1 FVIII was incubated with the plasma of naive FVIII (-/-) mice for 0, 24 and 48 h. Residual conformational integrity of FVIII was determined by ELISA measuring binding of FVIII to mAbs BO2C11 and GMA 8006 as described in the Materials and Methods. Binding is presented as a percentage of binding compared to values at time-point 0 h. Error bars represent the SD of the mean of duplicates. Fig. S2 . Binding of anti-IgG from the plasma of immunized FVIII knockout mice. Murine plasma samples from immunized FVIII (À/À) mice were diluted 1 : 100. Binding of murine IgG to FVIII, HC, LC and HSA-FVIII domains was tested by ELISA as recently described [29] . Spleens from mice 1-4 were collected, and splenocytes were utilized in the ex vivo cytotoxicity assay. Error bars represent the standard deviation (SD) of the mean of duplicates. 
